




RealRate

PHARMACEUTICAL 2023

Eagle Pharmaceuticals INC
Rank 186 of 471

EAGLE
PHARMACEUTICALS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Eagle Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eagle Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Eagle Pharmaceuticals INC is the variable Assets, Current, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 294%, being 50% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	188,754
Cost of Goods Sold	85,458
Intangible Assets	163,360
Liabilities, Current	111,087
Liabilities, Non-Current	61,513
Other Assets	52,878
Other Compr. Net Income	-1,018
Other Expenses	35,269
Other Liabilities	0
Other Net Income	-19,527
Other Revenues	316,610
Property and Equipment	1,168
Research and Development	34,088
Selling, General and Administrative Expense	106,626

Output Variable	Value in 1000 USD
Assets	406,160
Liabilities	172,600
Expenses	261,441
Revenues	316,610
Stockholders Equity	233,560
Net Income	35,642
Comprehensive Net Income	35,133
BaseVar	588,678
ECR before LimitedLiability	188%
Economic Capital Ratio	294%